[ET Net News Agency, 11 July 2018] CSPC Pharmaceutical Group (01093) said it has
entered into a product co-development and strategic collaboration agreement with Shanghai
Junshi Biosciences Co. regarding the clinical development, registration and
commercialization of PD-1 (the anti-PD-1 monoclonal antibody exclusively supplied by
Junshi) in combination with albumin-bound paclitaxel for the treatment of breast cancer.
Pursuant to the deal, the companies shall form a joint research committee to formulate
clinical strategy for the development of the product; establish and monitor the clinical
trials timeline and progress; ensure the full access of clinical data by both parties;
discuss and make decision on combination studies of PD-1 with albumin-bound paclitaxel and
other chemotherapeutic agents; and resolve any issues that arise during the process of the
development and registration of the product.
CSPC agrees to pay to Junshi a milestone payment of RMB30 million at each of the five
milestone events leading to the product approval and issuance of product licence by the
China Drug Administration for the Product. Junshi is an innovative biopharmaceutical
company based in China focusing on discovering and developing monoclonal antibody drugs.
(KL)